Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells

István Pályi, Gizella Turi, Lehel Hullán, Károly Szikla, M. Bak

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cultured P388/VCR mouse lymphoma cells resistant to vincristine (VCR) and to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1,2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act. D), in a dominant manner. The presence of glycoprotein p170, the MDR gene product, was detected in the hybrid cells. Resistance to DAG was also expressed dominantly, whereas cross-resistance to dibromodulcitol (DBD), a chemically related anticancer drug, was slight.

Original languageEnglish
Pages (from-to)81-85
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 1994

Fingerprint

Dianhydrogalactitol
Hybrid Cells
Multiple Drug Resistance
Vincristine
Lymphoma
Bromodeoxyuridine
Mitolactol
MDR Genes
Thioguanine
Hypoxanthine Phosphoribosyltransferase
Hypoxanthine
Thymidine Kinase
Alkylating Agents
Dactinomycin
Transferases
Antineoplastic Agents
Doxorubicin
Glycoproteins
Genes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells. / Pályi, István; Turi, Gizella; Hullán, Lehel; Szikla, Károly; Bak, M.

In: Cancer Chemotherapy and Pharmacology, Vol. 34, No. 1, 01.1994, p. 81-85.

Research output: Contribution to journalArticle

Pályi, István ; Turi, Gizella ; Hullán, Lehel ; Szikla, Károly ; Bak, M. / Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 34, No. 1. pp. 81-85.
@article{7e3f6137a5544f0793b8f2ef70c2a566,
title = "Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells",
abstract = "Cultured P388/VCR mouse lymphoma cells resistant to vincristine (VCR) and to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1,2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act. D), in a dominant manner. The presence of glycoprotein p170, the MDR gene product, was detected in the hybrid cells. Resistance to DAG was also expressed dominantly, whereas cross-resistance to dibromodulcitol (DBD), a chemically related anticancer drug, was slight.",
author = "Istv{\'a}n P{\'a}lyi and Gizella Turi and Lehel Hull{\'a}n and K{\'a}roly Szikla and M. Bak",
year = "1994",
month = "1",
doi = "10.1007/BF00686118",
language = "English",
volume = "34",
pages = "81--85",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells

AU - Pályi, István

AU - Turi, Gizella

AU - Hullán, Lehel

AU - Szikla, Károly

AU - Bak, M.

PY - 1994/1

Y1 - 1994/1

N2 - Cultured P388/VCR mouse lymphoma cells resistant to vincristine (VCR) and to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1,2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act. D), in a dominant manner. The presence of glycoprotein p170, the MDR gene product, was detected in the hybrid cells. Resistance to DAG was also expressed dominantly, whereas cross-resistance to dibromodulcitol (DBD), a chemically related anticancer drug, was slight.

AB - Cultured P388/VCR mouse lymphoma cells resistant to vincristine (VCR) and to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1,2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act. D), in a dominant manner. The presence of glycoprotein p170, the MDR gene product, was detected in the hybrid cells. Resistance to DAG was also expressed dominantly, whereas cross-resistance to dibromodulcitol (DBD), a chemically related anticancer drug, was slight.

UR - http://www.scopus.com/inward/record.url?scp=0028229213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028229213&partnerID=8YFLogxK

U2 - 10.1007/BF00686118

DO - 10.1007/BF00686118

M3 - Article

C2 - 7909724

AN - SCOPUS:0028229213

VL - 34

SP - 81

EP - 85

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -